The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis.
Détails
ID Serval
serval:BIB_C1F31C62ECAE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis.
Périodique
Ocular immunology and inflammation
ISSN
1744-5078 (Electronic)
ISSN-L
0927-3948
Statut éditorial
Publié
Date de publication
30/09/2020
Peer-reviewed
Oui
Volume
28
Numéro
sup1
Pages
38-48
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Purpose: To contribute a global description of the spectrum of choroidal involvement in tubercular uveitis (TBU).Methods: Retrospective cohort study of TBU patients with choroidal involvement from 25 centers between January 2004 and December 2014. Medical records of patients with a minimum follow-up of 1 year were reviewed.Results: 245 patients were included. The phenotypic variations included serpiginous-like choroiditis (SLC) (46%), tuberculoma (13.5%), multifocal choroiditis (MFC) (9.4%), ampiginous choroiditis (9%), among others. 219 patients were treated with anti-tubercular therapy (ATT) (n = 219/245, 89.38%), 229 patients with steroids (n = 229/245, 93.47%) and 28 patients with immunosuppressive agents (n = 28/245, 11.42%). Treatment failure was noted in 38 patients (n = 38/245, 15.5%). Patients with SLC and ampiginous choroiditis appeared to have superior outcomes on survival analysis (p = 0.06).Conclusion: This study provides a comprehensive description of choroidal involvement in TBU. Patients with SLC and ampiginous choroiditis may have better clinical outcomes.
Mots-clé
Anti-tubercular therapy, choroiditis, ocular, tuberculosis, uveitis
Pubmed
Web of science
Création de la notice
03/09/2018 14:00
Dernière modification de la notice
02/02/2023 7:52